International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
暂无分享,去创建一个
M. Herkenham | F. Barth | M. Herkenham | K. Mackie | T. Bonner | P. Casellas | R. Mechoulam | A. Howlett | W. Devane | R. Pertwee | F. Barth | B. Martin | C. Felder | C. C. Felder | R. Mechoulam | W. A. Devane | A. C. Howlett | T. I. Bonner | G. Cabral | P. Casellas | K. Mackie | B. R. Martin | R. G. Pertwee | G. Cabral
[1] E. Schlicker,et al. Cannabinoid receptor-mediated inhibition of dopamine release in the retina , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.
[2] T. Järbe,et al. Stimulus effects of Δ9-THC and its interaction with naltrexone and catecholamine blockers in rats , 1977, Psychopharmacology.
[3] D. McMillan,et al. Δ9-THC as a discriminative stimulus in rats and pigeons: Generalization to THC metabolites and SP-111 , 2004, Psychopharmacology.
[4] R. Pertwee,et al. Cannabinoid receptors and their ligands , 2002, European Neuropsychopharmacology.
[5] M. Parsons,et al. Modulation of the release of endogenous gamma-aminobutyric acid by cannabinoids in the guinea pig ileum. , 2002, European journal of pharmacology.
[6] K. Mackie,et al. Short-Term Retrograde Inhibition of GABAergic Synaptic Currents in Rat Purkinje Cells Is Mediated by Endogenous Cannabinoids , 2002, The Journal of Neuroscience.
[7] D. Deutsch,et al. The fatty acid amide hydrolase (FAAH). , 2000, Prostaglandins, leukotrienes, and essential fatty acids.
[8] G. Cabral,et al. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. , 2002, International immunopharmacology.
[9] L. Acsády,et al. Distribution of CB1 Cannabinoid Receptors in the Amygdala and their Role in the Control of GABAergic Transmission , 2001, The Journal of Neuroscience.
[10] T. Freund,et al. Evidence for presynaptic cannabinoid CB(1) receptor-mediated inhibition of noradrenaline release in the guinea pig lung. , 2001, European journal of pharmacology.
[11] M. Kathmann,et al. Modulation of transmitter release via presynaptic cannabinoid receptors. , 2001, Trends in pharmacological sciences.
[12] Anatol C. Kreitzer,et al. Cerebellar Depolarization-Induced Suppression of Inhibition Is Mediated by Endogenous Cannabinoids , 2001, The Journal of Neuroscience.
[13] J. Laitinen,et al. Despite substantial degradation, 2‐arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor‐dependent G‐protein activation in rat cerebellar membranes , 2001, British journal of pharmacology.
[14] D. Ponde,et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide , 2001, British journal of pharmacology.
[15] T. Freund,et al. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus , 2001, Neuroscience.
[16] R. Pertwee,et al. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea‐pig bronchus , 2001, British journal of pharmacology.
[17] G. Gessa,et al. Effects of chronic Δ9-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze , 2001, Neuropharmacology.
[18] K. Waku,et al. 2-Arachidonoylglycerol and anandamide oppositely modulate norepinephrine release from the rat heart sympathetic nerves. , 2001, Japanese journal of pharmacology.
[19] H. Kilbinger,et al. Differential effects of anandamide on acetylcholine release in the guinea‐pig ileum mediated via vanilloid and non‐CB1 cannabinoid receptors , 2001, British journal of pharmacology.
[20] A. Lichtman,et al. Differential effects of Δ9-THC on spatial reference and working memory in mice , 2001, Psychopharmacology.
[21] N. Stella,et al. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. , 2001, European journal of pharmacology.
[22] M. Kano,et al. Presynaptic Inhibition Caused by Retrograde Signal from Metabotropic Glutamate to Cannabinoid Receptors , 2001, Neuron.
[23] L. Ferraro,et al. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. , 2001, Cerebral cortex.
[24] M. Christie,et al. Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro , 2001, The Journal of physiology.
[25] B. Cravatt,et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[26] W. Feng,et al. Functional roles of the tyrosine within the NP(X) n Y motif and the cysteines in the C‐terminal juxtamembrane region of the CB2 cannabinoid receptor , 2001, FEBS letters.
[27] C. Newton,et al. Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. , 2001, European journal of pharmacology.
[28] C. Breivogel,et al. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. , 2001, Molecular pharmacology.
[29] M. Pistis,et al. Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation , 2001, The European journal of neuroscience.
[30] V. Morisset,et al. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. , 2001, Journal of neurophysiology.
[31] C. Ledent,et al. The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. , 2001, Biochemical and biophysical research communications.
[32] T. Bonner,et al. Dysregulated Cannabinoid Signaling Disrupts Uterine Receptivity for Embryo Implantation* , 2001, The Journal of Biological Chemistry.
[33] G. Cabral. Marijuana and Cannabinoids , 2001 .
[34] R. Pertwee. Cannabinoids and the gastrointestinal tract , 2001, Gut.
[35] G. Chiara,et al. Δ9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study , 2001 .
[36] D. Piomelli,et al. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. , 2001, European journal of pharmacology.
[37] K. Hsu,et al. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons , 2001, The Journal of physiology.
[38] I. Galve-Roperh,et al. The CB(1) cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. , 2001, Molecular pharmacology.
[39] T. Vanderah,et al. The Cannabinoid Agonist WIN55,212-2 Suppresses Opioid-induced Emesis in Ferrets , 2001, Anesthesiology.
[40] R. Palmiter,et al. Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.
[41] A. Randall,et al. Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology. , 2001, European journal of pharmacology.
[42] S. Heishman,et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. , 2001, Archives of general psychiatry.
[43] C. Felder,et al. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. , 2001, Pharmacology & therapeutics.
[44] M. Elphick,et al. The neurobiology and evolution of cannabinoid signalling. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[45] R. Nicoll,et al. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses , 2001, Nature.
[46] K. Connolly,et al. Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids , 2001, Neuroscience Letters.
[47] Z. Vogel,et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[48] D. Selley,et al. Inhibitory effects of SR141716A on G-protein activation in rat brain. , 2001, European journal of pharmacology.
[49] M. Grier,et al. Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation. , 2001, The Journal of pharmacology and experimental therapeutics.
[50] V. Chapman,et al. Cannabinoid inhibition of the capsaicin‐induced calcium response in rat dorsal root ganglion neurones , 2001, British journal of pharmacology.
[51] A. Christopoulos,et al. Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens , 2001, British journal of pharmacology.
[52] A. Zimmer,et al. Enhanced acetylcholine release in the hippocampus of cannabinoid CB1 receptor‐deficient mice , 2001, British journal of pharmacology.
[53] M. Kano,et al. Endogenous Cannabinoids Mediate Retrograde Signals from Depolarized Postsynaptic Neurons to Presynaptic Terminals , 2001, Neuron.
[54] Anatol C. Kreitzer,et al. Retrograde Inhibition of Presynaptic Calcium Influx by Endogenous Cannabinoids at Excitatory Synapses onto Purkinje Cells , 2001, Neuron.
[55] L. Petrocellis,et al. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. , 2001, Biochemical and biophysical research communications.
[56] C. Créminon,et al. Anandamide Excites Central Terminals of Dorsal Root Ganglion Neurons via Vanilloid Receptor-1 Activation , 2001, The Journal of Neuroscience.
[57] V. Di Marzo,et al. Structure‐activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens , 2001, British journal of pharmacology.
[58] P. Robson,et al. Therapeutic aspects of cannabis and cannabinoids , 2001, British Journal of Psychiatry.
[59] S. O’Brien,et al. Molecular phylogenetics and the origins of placental mammals , 2001, Nature.
[60] V. Pickel,et al. Ultrastructural Localization of the CB1 Cannabinoid Receptor in μ-Opioid Receptor Patches of the Rat Caudate Putamen Nucleus , 2001, The Journal of Neuroscience.
[61] O. Manzoni,et al. Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens. , 2001, European journal of pharmacology.
[62] M. Parmentier,et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse , 2001, Behavioural Brain Research.
[63] David Robbe,et al. Localization and Mechanisms of Action of Cannabinoid Receptors at the Glutamatergic Synapses of the Mouse Nucleus Accumbens , 2001, The Journal of Neuroscience.
[64] I. Galve-Roperh,et al. Ceramide: a new second messenger of cannabinoid action. , 2001, Trends in pharmacological sciences.
[65] D. Lovinger,et al. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. , 2001, Journal of neurophysiology.
[66] A. Hoffman,et al. Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids. , 2001, Journal of neurophysiology.
[67] N. Volkow,et al. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281 , 2000, Synapse.
[68] C. Breivogel,et al. Levels, Metabolism, and Pharmacological Activity of Anandamide in CB1 Cannabinoid Receptor Knockout Mice , 2000 .
[69] H. Ehrenreich,et al. Comparative sequencing of the human CB1 cannabinoid receptor gene coding exon: no structural mutations in individuals exhibiting extreme responses to cannabis. , 2000, Psychiatric genetics.
[70] Z. Vogel,et al. Functional Role of Tryptophan Residues in the Fourth Transmembrane Domainof the CB2 Cannabinoid Receptor , 2000, Journal of neurochemistry.
[71] A. Howlett,et al. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. , 2000, Chemistry and physics of lipids.
[72] A. Howlett,et al. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. , 2000, Biochemical pharmacology.
[73] C. Hillard,et al. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. , 2000, Chemistry and physics of lipids.
[74] E. Berdyshev,et al. Cannabinoid receptors and the regulation of immune response. , 2000, Chemistry and physics of lipids.
[75] P. Reggio,et al. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. , 2000, Chemistry and physics of lipids.
[76] S. Goparaju,et al. Endocannabinoids as cardiovascular modulators. , 2000, Chemistry and physics of lipids.
[77] K. Starke,et al. Electrically Evoked Release of [3H]Noradrenaline from Mouse Cultured Sympathetic Neurons , 2000, Journal of neurochemistry.
[78] C. Breivogel,et al. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. , 2000, European journal of pharmacology.
[79] T. Bisogno,et al. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity , 2000, FEBS letters.
[80] S. Bevan,et al. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons , 2000, Neuroscience.
[81] T. Freund,et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus , 2000, Neuroscience.
[82] C. Newton,et al. Anti-CD40, anti-CD3, and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes , 2000, Journal of Neuroimmunology.
[83] I. Galve-Roperh,et al. The CB1 Cannabinoid Receptor Is Coupled to the Activation of c-Jun N-Terminal Kinase , 2000 .
[84] D. Deutsch,et al. 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. , 2000, Pharmacological research.
[85] N. Volkow,et al. Cannabinoid receptor‐mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes , 2000, British journal of pharmacology.
[86] A. Al-Hayani,et al. Cannabinoid receptor mediated inhibition of excitatory synaptic transmission in the rat hippocampal slice is developmentally regulated , 2000, British journal of pharmacology.
[87] P. Sacerdote,et al. In vivo and in vitro treatment with the synthetic cannabinoid CP55,940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors , 2000, Journal of Neuroimmunology.
[88] A. Lichtman. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. , 2000, European journal of pharmacology.
[89] I. Módy,et al. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations , 2000, The European journal of neuroscience.
[90] A. Makriyannis,et al. Natural and synthetic endocannabinoids and their structure-activity relationships. , 2000, Current pharmaceutical design.
[91] J. Cheer,et al. Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study , 2000, Neuroscience.
[92] G. Di Chiara,et al. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. , 2000, European journal of pharmacology.
[93] D. Kendall,et al. Vanilloid receptors on capsaicin‐sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries , 2000, British journal of pharmacology.
[94] G. Gessa,et al. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain , 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[95] P Ferrara,et al. Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. , 2000, European journal of pharmacology.
[96] Li Zhu,et al. Δ-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway1 , 2000, The Journal of Immunology.
[97] G. Gessa,et al. D2 dopamine receptors enable Δ9‐tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration , 2000, British journal of pharmacology.
[98] R. Pertwee. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development , 2000, Expert opinion on investigational drugs.
[99] M. Elphick,et al. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C‐terminal tail of CB1 , 2000, The Journal of comparative neurology.
[100] C. Newton,et al. Δ9-Tetrahydrocannabinol Treatment Suppresses Immunity and Early IFN-γ, IL-12, and IL-12 Receptor β2 Responses to Legionella pneumophila Infection1 , 2000, The Journal of Immunology.
[101] K. Mackie,et al. Functional expression of cell surface cannabinoid CB1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons , 2000, Neuroscience.
[102] W. Campbell,et al. Structure—Activity Relationships Among N‐Arachidonylethanolamine (Anandamide) Head Group Analogues for the Anandamide Transporter , 2000, Journal of neurochemistry.
[103] D. Piomelli,et al. The endocannabinoid system as a target for therapeutic drugs. , 2000, Trends in pharmacological sciences.
[104] P. Soubrié,et al. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. , 2000, Journal of neurophysiology.
[105] T. Bonner,et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. , 2000, European journal of pharmacology.
[106] P. Zygmunt,et al. The anandamide transport inhibitor AM404 activates vanilloid receptors. , 2000, European journal of pharmacology.
[107] A. Finazzi-Agro’,et al. Anandamide Uptake by Human Endothelial Cells and Its Regulation by Nitric Oxide* , 2000, The Journal of Biological Chemistry.
[108] S. Narula,et al. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. , 2000, Molecular pharmacology.
[109] K. Starke,et al. Modulation of 3H‐noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and β‐adrenoceptors in mouse tissues , 2000, British journal of pharmacology.
[110] L. Walch,et al. Evidence for a M1 muscarinic receptor on the endothelium of human pulmonary veins , 2000, British journal of pharmacology.
[111] A. Makriyannis,et al. Azido‐ and Isothiocyanato‐Substituted Aryl Pyrazoles Bind Covalently to the CB1 Cannabinoid Receptor and Impair Signal Transduction , 2000, Journal of neurochemistry.
[112] G. Velasco,et al. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. , 2000, The Biochemical journal.
[113] R. Pertwee,et al. O‐1057, a potent water‐soluble cannabinoid receptor agonist with antinociceptive properties , 2000, British journal of pharmacology.
[114] A. Hoffman,et al. Mechanisms of Cannabinoid Inhibition of GABAASynaptic Transmission in the Hippocampus , 2000, The Journal of Neuroscience.
[115] B. Szabo,et al. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata , 2000, Neuroscience.
[116] A. Makriyannis,et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. , 2000, The Biochemical journal.
[117] A. Izzo,et al. Modulation of peristalsis by cannabinoid CB1 ligands in the isolated guinea‐pig ileum , 2000, British journal of pharmacology.
[118] P. Casellas,et al. A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis , 2000, Journal of leukocyte biology.
[119] G. Griffin,et al. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. , 2000, The Journal of pharmacology and experimental therapeutics.
[120] D. Linden,et al. Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. , 2000, Journal of neurophysiology.
[121] R. Pertwee,et al. Comparison of novel cannabinoid partial agonists and SR141716A in the guinea‐pig small intestine , 2000, British journal of pharmacology.
[122] Michael L. Eads,et al. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Δ9-THC and anandamide 1 Published on the World Wide Web on 18 January 2000. 1 , 2000, Brain Research.
[123] E. E. Bagley,et al. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. , 2000, Molecular pharmacology.
[124] Z. Vogel,et al. Role of the highly conserved Asp‐Arg‐Tyr motif in signal transduction of the CB2 cannabinoid receptor , 2000, FEBS letters.
[125] P. Massi,et al. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. , 2000, European journal of pharmacology.
[126] K. Waku,et al. Evidence That 2-Arachidonoylglycerol but Not N-Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 Receptor , 2000, The Journal of Biological Chemistry.
[127] R. Pertwee,et al. Neuropharmacology and therapeutic potential of cannabinoids , 2000, Addiction biology.
[128] J. Chambers,et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) , 2000, British journal of pharmacology.
[129] D. Middlemiss,et al. The anandamide transport inhibitor AM404 is an agonist at the rat vanilloid receptor (VR1) , 2000 .
[130] C. Breivogel,et al. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. , 2000, Journal of neurochemistry.
[131] Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.
[132] I. Galve-Roperh,et al. The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. , 2000, Molecular pharmacology.
[133] I. Galve-Roperh,et al. Involvement of the cAMP/protein kinase A pathway and of mitogen‐activated protein kinase in the anti‐proliferative effects of anandamide in human breast cancer cells , 1999, FEBS letters.
[134] R. Mechoulam,et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[135] S. Yu,et al. 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. , 1999, Bioorganic & medicinal chemistry.
[136] G. Marsicano,et al. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain , 1999, The European journal of neuroscience.
[137] G. Coruzzi,et al. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[138] T. Bonner,et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[139] M. Parmentier,et al. Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. , 1999, European journal of pharmacology.
[140] M. Parmentier,et al. Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors , 1999, Neuroscience.
[141] S. McAllister,et al. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. , 1999, The Journal of pharmacology and experimental therapeutics.
[142] J. Murphy,et al. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. , 1999, The Journal of pharmacology and experimental therapeutics.
[143] N. Volkow,et al. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). , 1999, European journal of pharmacology.
[144] J. G. Netzeband,et al. Cannabinoids Enhance NMDA-Elicited Ca2+ Signals in Cerebellar Granule Neurons in Culture , 1999, The Journal of Neuroscience.
[145] J. Walker,et al. Pain modulation by release of the endogenous cannabinoid anandamide. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[146] Patricia H. Reggio,et al. The Difference between the CB1 and CB2Cannabinoid Receptors at Position 5.46 Is Crucial for the Selectivity of WIN55212-2 for CB2 , 1999 .
[147] R. Pertwee,et al. Structural determinants of the partial agonist‐inverse agonist properties of 6′‐azidohex‐2′‐yne‐Δ8‐tetrahydrocannabinol at cannabinoid receptors , 1999, British journal of pharmacology.
[148] N. Standen,et al. Cannabinoid CB1 receptors fail to cause relaxation, but couple via Gi/Go to the inhibition of adenylyl cyclase in carotid artery smooth muscle , 1999, British journal of pharmacology.
[149] N. Delzenne,et al. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. , 1999, Biochimica et biophysica acta.
[150] K. Mackie,et al. A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization. , 1999, Molecular pharmacology.
[151] J. Sullivan,et al. Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons. , 1999, Journal of neurophysiology.
[152] M. Parmentier,et al. Enhancement of memory in cannabinoid CB1 receptor knock-out mice. , 1999, European journal of pharmacology.
[153] J. Sullivan,et al. Mechanism of Cannabinoid Effects on Long-Term Potentiation and Depression in Hippocampal CA1 Neurons , 1999, The Journal of Neuroscience.
[154] R. Pertwee,et al. Pharmacology of cannabinoid receptor ligands. , 1999, Current medicinal chemistry.
[155] K. Mackie,et al. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation , 1999, Neuroscience.
[156] J. Huffman. Cannabimimetic indoles, pyrroles and indenes. , 1999, Current medicinal chemistry.
[157] M. Rinaldi-Carmona,et al. The development of cannabinoid antagonists. , 1999, Current medicinal chemistry.
[158] K. Müller-Vahl,et al. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. , 1999, Molecular and cellular probes.
[159] L. Petrocellis,et al. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. , 1999, Current medicinal chemistry.
[160] P. Reggio. Ligand-ligand and ligand-receptor approaches to modeling the cannabinoid CB1 and CB2 receptors: achievements and challenges. , 1999, Current medicinal chemistry.
[161] G. Molderings,et al. Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[162] D. Julius,et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.
[163] R. Mechoulam,et al. Discovery and characterization of endogenous cannabinoids. , 1999, Life sciences.
[164] A. Makriyannis,et al. Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. , 1999, Life sciences.
[165] M. Guzmán,et al. Effects of cannabinoids on energy metabolism. , 1999, Life sciences.
[166] A. Howlett,et al. Adenylyl Cyclase, a Coincidence Detector for Nitric Oxide* , 1999, The Journal of Biological Chemistry.
[167] A. Ameri. The effects of cannabinoids on the brain , 1999, Progress in Neurobiology.
[168] M. Kathmann,et al. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[169] W. Campbell,et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). , 1999, The Journal of pharmacology and experimental therapeutics.
[170] W. Campbell,et al. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. , 1999, The American journal of physiology.
[171] Ken Mackie,et al. Presynaptically Located CB1 Cannabinoid Receptors Regulate GABA Release from Axon Terminals of Specific Hippocampal Interneurons , 1999, The Journal of Neuroscience.
[172] I. McGregor,et al. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro , 1999, British journal of pharmacology.
[173] C. Hillard,et al. Relationships Between Ligand Affinities for the Cerebellar Cannabinoid Receptor CB1 and the Induction of GDP/GTP Exchange , 1999, Journal of neurochemistry.
[174] G. Cabral,et al. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. , 1999, The Journal of pharmacology and experimental therapeutics.
[175] D. Piomelli,et al. Structural determinants for recognition and translocation by the anandamide transporter. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[176] H. Steiner,et al. Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[177] M. Herkenham,et al. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[178] P. Casellas,et al. Cannabinoid receptor CB1 activates the Na+/H+ exchanger NHE‐1 isoform via Gi‐mediated mitogen activated protein kinase signaling transduction pathways , 1999, FEBS letters.
[179] W. Graier,et al. Anandamide‐induced mobilization of cytosolic Ca2+ in endothelial cells , 1999, British journal of pharmacology.
[180] I. Galve-Roperh,et al. The Stimulation of Ketogenesis by Cannabinoids in Cultured Astrocytes Defines Carnitine Palmitoyltransferase I as a New Ceramide‐Activated Enzyme , 1999, Journal of neurochemistry.
[181] L. Parsons,et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum , 1999, Nature Neuroscience.
[182] G. Cabral,et al. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. , 1999, The Journal of pharmacology and experimental therapeutics.
[183] D. Deutsch,et al. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. , 1999, Cellular signalling.
[184] J. Andreassi,et al. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. , 1999, Molecular pharmacology.
[185] A. Makriyannis,et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. , 1999, Journal of medicinal chemistry.
[186] R. Pertwee,et al. Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630 , 1999, British journal of pharmacology.
[187] H. Moore,et al. Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release , 1999, Neuroscience.
[188] P. Casellas,et al. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. , 1999, The Journal of pharmacology and experimental therapeutics.
[189] K. Waku,et al. Evidence That the Cannabinoid CB1 Receptor Is a 2-Arachidonoylglycerol Receptor , 1999, The Journal of Biological Chemistry.
[190] M. Parmentier,et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. , 1999, Science.
[191] G. Kunos,et al. Mesenteric vasodilation mediated by endothelial anandamide receptors. , 1999, Hypertension.
[192] V. Di Marzo. Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. , 1999, Life sciences.
[193] M. Thiébot,et al. Behavioral Effects of Cannabinoid Agents in Animals. , 1999, Critical reviews in neurobiology.
[194] D. Hurst,et al. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). , 1999, Molecular pharmacology.
[195] M. Shen,et al. Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. , 1999, Molecular pharmacology.
[196] M. Kathmann,et al. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[197] K. Mackie,et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system , 1998, Neuroscience.
[198] N. Kaminski,et al. Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds. , 1998, Toxicology letters.
[199] A. Makriyannis,et al. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. , 1998, Journal of medicinal chemistry.
[200] A. Lichtman,et al. Cannabinoid Transmission and Pain Perception , 1998, Neurobiology of Disease.
[201] S. Ikeda,et al. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. , 1998, Molecular pharmacology.
[202] L. Petrocellis,et al. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action , 1998, Trends in Neurosciences.
[203] M. Maccarrone,et al. Anandamide Hydrolysis by Human Cells in Culture and Brain* , 1998, The Journal of Biological Chemistry.
[204] S. Galiègue,et al. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. , 1998, Blood.
[205] M. Elphick,et al. A new perspective on cannabinoid signalling: complimentary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. , 1998, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[206] R. Pertwee,et al. Comparison of cannabinoid binding sites in guinea‐pig forebrain and small intestine , 1998, British journal of pharmacology.
[207] I. Galve-Roperh,et al. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. , 1998, Molecular pharmacology.
[208] G. Gessa,et al. Inhibition of hippocampal acetylcholine release after acute and repeated Δ9-tetrahydrocannabinol in rats , 1998, Brain Research.
[209] D. Deutsch,et al. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry , 1998, Neuroscience Letters.
[210] Z. Vogel,et al. Cannabinoid Receptor Activation Differentially Regulates the Various Adenylyl Cyclase Isozymes , 1998, Journal of neurochemistry.
[211] A. Lichtman,et al. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. , 1998, European journal of pharmacology.
[212] R. Pertwee,et al. Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice , 1998, Neuropharmacology.
[213] M. Shen,et al. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. , 1998, Molecular pharmacology.
[214] J. Lowe,et al. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. , 1998, The Journal of pharmacology and experimental therapeutics.
[215] G. Gessa,et al. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. , 1998, European journal of pharmacology.
[216] C. Paronis. ANTAGONISM OF THE DISCRIMINATIVE STIMULUS EFFECTS OF MIDAZOLAM BY FLUMAZENIL AND BRETAZENIL IN SQUIRREL MONKEYS , 1998 .
[217] P. Soubrié,et al. Cannabinoids decrease excitatory synaptic transmission and impair long‐term depression in rat cerebellar Purkinje cells , 1998, The Journal of physiology.
[218] L. Petrocellis,et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. , 1998, European journal of pharmacology.
[219] D. Piomelli,et al. Control of pain initiation by endogenous cannabinoids , 1998, Nature.
[220] L. Petrocellis,et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[221] D. Selley,et al. Cannabinoid Receptor Agonist Efficacy for Stimulating [35S]GTPγS Binding to Rat Cerebellar Membranes Correlates with Agonist-induced Decreases in GDP Affinity* , 1998, The Journal of Biological Chemistry.
[222] A. Howlett,et al. Effects of nitric oxide on adenylyl cyclase stimulation in N18TG2 neuroblastoma cells. , 1998, The Journal of pharmacology and experimental therapeutics.
[223] J. A. Patel,et al. Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain , 1998, Brain Research.
[224] W. Yung,et al. Occlusion of the presynaptic action of cannabinoids in rat substantia nigra pars reticulata by cadmium , 1998, Neuroscience Letters.
[225] T. Bilfinger,et al. Antagonism of LPS and IFN-gamma induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase. , 1998, Journal of cardiovascular pharmacology.
[226] D. Bonhaus,et al. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors , 1998, British journal of pharmacology.
[227] D. R. Compton,et al. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. , 1998, The Journal of pharmacology and experimental therapeutics.
[228] M. Abood,et al. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. , 1998, The Journal of pharmacology and experimental therapeutics.
[229] G. Griffin,et al. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. , 1998, The Journal of pharmacology and experimental therapeutics.
[230] V. Prévot,et al. Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: neurovascular regulation , 1998, Brain Research.
[231] K. Starke,et al. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum , 1998, Neuroscience.
[232] B. Thomas,et al. Comparative receptor binding analyses of cannabinoid agonists and antagonists. , 1998, The Journal of pharmacology and experimental therapeutics.
[233] W. Yung,et al. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist , 1998, Neuroreport.
[234] D. R. Compton,et al. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. , 1998, The Journal of pharmacology and experimental therapeutics.
[235] F. Barth. Cannabinoid receptor agonists and antagonists , 1998 .
[236] M. Shen,et al. The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons , 1998, Brain Research.
[237] P. Casellas,et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.
[238] M. Scanziani,et al. Dual Effects of Anandamide on NMDA Receptor‐Mediated Responses and Neurotransmission , 1998, Journal of neurochemistry.
[239] T. Bonner,et al. Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies , 1998, Journal of Neuroimmunology.
[240] A. Makriyannis,et al. AM630 is an inverse agonist at the human cannabinoid CB1 receptor. , 1998, Life sciences.
[241] G. Gessa,et al. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. , 1998, European journal of pharmacology.
[242] Payton King,et al. Imaging the Brain Marijuana Receptor: Development of a Radioligand that Binds to Cannabinoid CB1 Receptors In Vivo , 1998, Journal of neurochemistry.
[243] D. Kendall,et al. Ligand Binding and Modulation of Cyclic AMP Levels Depend on the Chemical Nature of Residue 192 of the Human Cannabinoid Receptor 1 , 1998, Journal of neurochemistry.
[244] J. Ramos,et al. The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. , 1997, Life sciences.
[245] K. Mackie,et al. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. , 1998, The Journal of pharmacology and experimental therapeutics.
[246] G. Gessa,et al. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. , 1998, The European journal of neuroscience.
[247] M. Glass,et al. Cannabinoid receptors and their endogenous agonists. , 1998, Annual review of pharmacology and toxicology.
[248] R. Razdan,et al. Evaluation of Cannabimimetic Discriminative Stimulus Effects of Anandamide and Methylated Fluoroanandamide in Rhesus Monkeys , 1997, Pharmacology Biochemistry and Behavior.
[249] N. Volkow,et al. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices , 1997, Neuroscience Letters.
[250] S. Yu,et al. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. , 1997, European journal of pharmacology.
[251] É. Mezey,et al. Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat , 1997, Neuroscience.
[252] J. Zentner,et al. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[253] R. Quock,et al. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. , 1997, European journal of pharmacology.
[254] I. Yamamoto,et al. Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells. , 1997, Journal of biochemistry.
[255] Z. Vogel,et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. , 1997, Journal of medicinal chemistry.
[256] H. Yamamura,et al. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. , 1997, European journal of pharmacology.
[257] P. Massi,et al. Changes in Rat Spleen Cannabinoid Receptors after Chronic CP-55,940: An Autoradiographic Study , 1997, Pharmacology Biochemistry and Behavior.
[258] Stephen P. H. Alexander,et al. Influence of Cannabinoids on Electrically Evoked Dopamine Release and Cyclic AMP Generation in the Rat Striatum , 1997, Journal of neurochemistry.
[259] C. Breivogel,et al. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. , 1997, The Journal of pharmacology and experimental therapeutics.
[260] N. Volkow,et al. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. , 1997, Life sciences.
[261] P. Casellas,et al. A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1 , 1997, The Journal of Biological Chemistry.
[262] D. Piomelli,et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. , 1997, Science.
[263] D. Piomelli,et al. A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.
[264] S. Mancham,et al. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. , 1997, Blood.
[265] R. Pertwee,et al. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea‐pig myenteric plexus , 1997, British journal of pharmacology.
[266] R. Quock,et al. AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. , 1997, Life sciences.
[267] A. Kustka,et al. Morphine- and anadamide-stimulated nitric oxide production inhibits presynaptic dopamine release , 1997, Brain Research.
[268] M. Glass,et al. Concurrent Stimulation of Cannabinoid Cb1 and Dopamine D2 Receptors Augments Camp Accumulation in Striatal Neurons: Evidence for a G S Linkage to the Cb1 Receptor , 1997 .
[269] Effects of cannabinoids , 1997, Science.
[270] G. Di Chiara,et al. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. , 1997, Science.
[271] C. Guaza,et al. Anandamide suppresses nitric oxide and TNF‐α responses to Theiler's virus or endotoxin in astrocytes , 1997, Neuroreport.
[272] G. Gessa,et al. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. , 1997, European journal of pharmacology.
[273] E. French. Δ 9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors , 1997, Neuroscience Letters.
[274] G. Kunos,et al. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. , 1997, Hypertension.
[275] G. Stefano,et al. Identification and characterization of the leech CNS cannabinoid receptor: coupling to nitric oxide release , 1997, Brain Research.
[276] A. Yamashita,et al. Inhibition by 2-arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma x glioma hybrid NG108-15 cells. , 1997, Biochemical and biophysical research communications.
[277] S. Gatley,et al. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. , 1997, European journal of pharmacology.
[278] Z. Vogel,et al. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. , 1997, Journal of medicinal chemistry.
[279] R. Faull,et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.
[280] R. Quock,et al. AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. , 1997, European journal of pharmacology.
[281] E. French,et al. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra , 1997, Neuroreport.
[282] N. Kaminski,et al. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. , 1997, Toxicology and applied pharmacology.
[283] L. Matsuda,et al. Molecular aspects of cannabinoid receptors. , 1997, Critical reviews in neurobiology.
[284] R. Pertwee. Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.
[285] R. Hampson,et al. Effects of Chronic Treatment with Δ9-Tetrahydrocannabinol on Cannabinoid-Stimulated [35S]GTPγS Autoradiography in Rat Brain , 1996, The Journal of Neuroscience.
[286] A. Yamashita,et al. 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells. , 1996, Biochemical and biophysical research communications.
[287] W. A. Hill,et al. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. , 1996, Journal of medicinal chemistry.
[288] P. Prasit,et al. NEW CLASS OF POTENT LIGANDS FOR THE HUMAN PERIPHERAL CANNABINOID RECEPTOR , 1996 .
[289] A. Makriyannis,et al. Preparation of iodine‐123 labeled AM251: A potential SPECT radioligand for the brain cannabinoid CB1 receptor , 1996 .
[290] D. R. Compton,et al. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. , 1996, Journal of medicinal chemistry.
[291] S. Deadwyler,et al. Role of cyclic AMP in the actions of cannabinoid receptors. , 1996, Biochemical pharmacology.
[292] J. Girault,et al. Regulation of a Neuronal Form of Focal Adhesion Kinase by Anandamide , 1996, Science.
[293] H. Rosenberg,et al. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA , 1996, Brain Research.
[294] W. A. Hill,et al. Unsaturated Side Chain β-11-Hydroxyhexahydrocannabinol Analogs , 1996 .
[295] Y. Yamamoto,et al. Tetrahydrocannabinol inhibition of macrophage nitric oxide production. , 1996, Biochemical pharmacology.
[296] D. R. Compton,et al. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. , 1996, The Journal of pharmacology and experimental therapeutics.
[297] M. Goligorsky,et al. Cannabinoid Receptors Are Coupled to Nitric Oxide Release in Invertebrate Immunocytes, Microglia, and Human Monocytes* , 1996, The Journal of Biological Chemistry.
[298] Y. Jeon,et al. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. , 1996, Molecular pharmacology.
[299] P. Casellas,et al. Characterization of two cloned human CB1 cannabinoid receptor isoforms. , 1996, The Journal of pharmacology and experimental therapeutics.
[300] J. Nash,et al. Further evidence for the presence of cannabinoid CB1 receptors in guinea‐pig small intestine , 1996, British journal of pharmacology.
[301] G. Kunos,et al. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB 1 receptors on peripheral sympathetic nerves , 1996, British journal of pharmacology.
[302] S. Childers,et al. Cannabinoid receptor stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding in rat brain membranes. , 1996, Life sciences.
[303] J. Brotchie,et al. Activation of the cannabinoid receptor by Δ9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus , 1996 .
[304] M. Shen,et al. Cannabinoid Receptor Agonists Inhibit Glutamatergic Synaptic Transmission in Rat Hippocampal Cultures , 1996, The Journal of Neuroscience.
[305] B. Ho,et al. Determination of the cannabinoid receptors in mouse × rat hybridoma NG108-15 cells and rat GH4C 1 cells , 1996, Neuroscience Letters.
[306] P. Ferrara,et al. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. , 1996, Biochimica et biophysica acta.
[307] C. Ashby,et al. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. , 1996, The Journal of pharmacology and experimental therapeutics.
[308] N. Kaminski,et al. Cannabinoid Inhibition of Adenylate Cyclase-mediated Signal Transduction and Interleukin 2 (IL-2) Expression in the Murine T-cell Line, EL4.IL-2* , 1996, The Journal of Biological Chemistry.
[309] T. Bonner,et al. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. , 1996, Molecular pharmacology.
[310] J. Lowe,et al. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. , 1996, The Journal of pharmacology and experimental therapeutics.
[311] P. Casellas,et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. , 1996, European journal of biochemistry.
[312] Z. Vogel,et al. ()--Tetrahydrocannabinol Antagonizes the Peripheral Cannabinoid Receptor-mediated Inhibition of Adenylyl Cyclase (*) , 1996, The Journal of Biological Chemistry.
[313] J. Brotchie,et al. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212‐2 , 1996, Synapse.
[314] S. Ikeda,et al. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. , 1996, Molecular pharmacology.
[315] P. Soubrié,et al. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. , 1996, Life sciences.
[316] G. Chaudhuri,et al. Cannabinoid receptor genes , 1996, Progress in Neurobiology.
[317] F. Petitet,et al. Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A , 1996, Neuroreport.
[318] Y. Daaka,et al. Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. , 1996, The Journal of pharmacology and experimental therapeutics.
[319] K. Metters,et al. Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors , 1996 .
[320] G. Cabral,et al. Cannabinoid receptor expression in immune cells. , 1996, Advances in experimental medicine and biology.
[321] P. Casellas,et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. , 1995, The Biochemical journal.
[322] Z. Vogel,et al. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling , 1995, FEBS letters.
[323] A. Yamashita,et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.
[324] K. Mackie,et al. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[325] J. Lowe,et al. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. , 1995, The Journal of pharmacology and experimental therapeutics.
[326] G. Griffin,et al. Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. , 1995, European journal of pharmacology.
[327] K. Mackie,et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. , 1995, Molecular pharmacology.
[328] M. Eissenstat,et al. Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. , 1995, Journal of medicinal chemistry.
[329] D. Selley,et al. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[330] G. O'neill,et al. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. , 1995, Molecular pharmacology.
[331] S. Galiègue,et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.
[332] Z. Vogel,et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.
[333] P. Casellas,et al. Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells (*) , 1995, The Journal of Biological Chemistry.
[334] R. L. Barrett,et al. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats , 1995, Neuropharmacology.
[335] G. Cabral,et al. delta 9-Tetrahydrocannabinol modulates antigen processing by macrophages. , 1995, The Journal of pharmacology and experimental therapeutics.
[336] S. Welch,et al. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. , 1995, The Journal of pharmacology and experimental therapeutics.
[337] A. Makriyannis,et al. AM630, a competitive cannabinoid receptor antagonist. , 1995, Life sciences.
[338] A. Buriani,et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[339] B. Martin,et al. Discriminative stimulus effects of anandamide in rats. , 1995, European journal of pharmacology.
[340] D. R. Compton,et al. 1-ALKYL-3-(1-NAPHTHOYL)PYRROLES : A NEW CLASS OF CANNABINOID , 1995 .
[341] M. Kaghad,et al. An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing (*) , 1995, The Journal of Biological Chemistry.
[342] C. Chavkin,et al. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes , 1995, Neuroscience Letters.
[343] M. Eissenstat,et al. Morpholinoalkylindenes as antinociceptive agents: Novel cannabinoid receptor agonists , 1995 .
[344] M. Wartmann,et al. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide , 1995, FEBS letters.
[345] G. Chaudhuri,et al. Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein. , 1995, DNA sequence : the journal of DNA sequencing and mapping.
[346] A. Howlett,et al. Pharmacology of cannabinoid receptors. , 1995, Annual review of pharmacology and toxicology.
[347] Y. Daaka,et al. Expression of cannabinoid receptor mRNA in murine and human leukocytes. , 1995, Advances in experimental medicine and biology.
[348] B. Thomas,et al. Structural requirements for cannabinoid receptor probes , 1994 .
[349] M. Kozak. Determinants of translational fidelity and efficiency in vertebrate mRNAs , 1994, Biochimie.
[350] N. Kaminski,et al. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. , 1994, Biochemical pharmacology.
[351] K. Rice,et al. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. , 1994, Molecular pharmacology.
[352] P. Soubrié,et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.
[353] A. Makriyannis,et al. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. , 1994, Journal of medicinal chemistry.
[354] M. Herkenham,et al. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. , 1994, The Journal of pharmacology and experimental therapeutics.
[355] John W. Huffman,et al. Design, synthesis and pharmacology of cannabimimetic indoles , 1994 .
[356] S. Childers,et al. Effects of anandamide on cannabinoid receptors in rat brain membranes. , 1994, Biochemical pharmacology.
[357] A. Howlett,et al. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. , 1993, Molecular pharmacology.
[358] S. Almog,et al. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. , 1993, Journal of medicinal chemistry.
[359] S. Munro,et al. Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.
[360] K. Mackie,et al. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. , 1993, Molecular pharmacology.
[361] K. Mackie,et al. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[362] R. Mechoulam,et al. Anandamide, a Brain Endogenous Compound, Interacts Specifically with Cannabinoid Receptors and Inhibits Adenylate Cyclase , 1993, Journal of neurochemistry.
[363] P. Casellas,et al. Cannabinoid-receptor expression in human leukocytes. , 1993, European journal of biochemistry.
[364] K. Rice,et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. , 1993, The Journal of pharmacology and experimental therapeutics.
[365] D. Haycock,et al. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. , 1993, The Journal of pharmacology and experimental therapeutics.
[366] S. Childers,et al. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells , 1993, Brain Research.
[367] T. Bonner,et al. Localization of cannabinoid receptor mRNA in rat brain , 1993, The Journal of comparative neurology.
[368] S A Deadwyler,et al. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. , 1993, The Journal of pharmacology and experimental therapeutics.
[369] D. Gibson,et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.
[370] L. Gold,et al. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. , 1992, The Journal of pharmacology and experimental therapeutics.
[371] B. Thomas,et al. Characterization and autoradiographic localization of the cannabinoid binding site in rat brain using [3H]11-OH-delta 9-THC-DMH. , 1992, The Journal of pharmacology and experimental therapeutics.
[372] N. Kaminski,et al. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. , 1992, Molecular pharmacology.
[373] L. Matsuda,et al. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. , 1992, Molecular pharmacology.
[374] Marc Parmentier,et al. Distribution of cannabinoid receptor messenger RNA in the human brain: An in situ hybridization histochemistry with oligonucleotides , 1992, Neuroscience Letters.
[375] R. L. Barrett,et al. A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. , 1992, The Journal of pharmacology and experimental therapeutics.
[376] D. Brown,et al. Cannabinoid receptor agonists inhibit Ca current in NG108–15 neuroblastoma cells via a Pertussis toxin‐sensitive mechanism , 1992, British journal of pharmacology.
[377] R. Mechoulam,et al. A novel probe for the cannabinoid receptor. , 1992, Journal of medicinal chemistry.
[378] K. Mackie,et al. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[379] R. Mechoulam,et al. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea‐pig small intestine , 1992, British journal of pharmacology.
[380] D. Haycock,et al. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles , 1992, Brain Research.
[381] W. R. Prescott,et al. Δ9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication , 1992, Neuroscience & Biobehavioral Reviews.
[382] M. Johnson,et al. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. , 1992, The Journal of pharmacology and experimental therapeutics.
[383] M. Eissenstat,et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. , 1992, Journal of medicinal chemistry.
[384] B. Martin,et al. Neurobiology of marijuana abuse. , 1992, Trends in pharmacological sciences.
[385] R. Mechoulam,et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs , 1991, Pharmacology Biochemistry and Behavior.
[386] R. Mechoulam,et al. A random walk through a cannabis field , 1991, Pharmacology Biochemistry and Behavior.
[387] G Vassart,et al. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. , 1991, The Biochemical journal.
[388] J. Lowinson,et al. Strain-specific facilitation of dopamine efflux by Δ 9-tetrahydrocannabinol in the nucleus accumbens of rat: An in vivo microdialysis study , 1991, Neuroscience Letters.
[389] G. Concílio,et al. Reversible effects of acute and long-term administration of delta-9-tetrahydrocannabinol (THC) on memory in the rat. , 1991, Drug and alcohol dependence.
[390] S. Childers,et al. Aminoalkylindoles: actions on specific G-protein-linked receptors. , 1991, The Journal of pharmacology and experimental therapeutics.
[391] J. R. Wetzel,et al. Antinociceptive (aminoalkyl)indoles. , 1991, Journal of medicinal chemistry.
[392] M. Herkenham,et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[393] Eliot L. Gardner,et al. Δ9-Tetrahydroeannabinol enhances presynaptic dopamine efflux In medial prefrontal cortex , 1990 .
[394] T. Bonner,et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.
[395] M. Herkenham,et al. Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[396] R. Mechoulam,et al. Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. , 1990, Neuropharmacology.
[397] M. Parmentier,et al. Nucleotide sequence of a human cannabinoid receptor cDNA. , 1990, Nucleic acids research.
[398] A. Hiltunen,et al. Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons. , 1989, The Journal of pharmacology and experimental therapeutics.
[399] P. Little,et al. Stereochemical effects of 11-OH-Δ 8-THC-dimethylheptyl in mice and dogs , 1989, Pharmacology Biochemistry and Behavior.
[400] P. Little,et al. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. , 1988, The Journal of pharmacology and experimental therapeutics.
[401] A. Howlett,et al. Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.
[402] A. Howlett,et al. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. , 1988, Molecular pharmacology.
[403] J. Scimeca,et al. Studies on the agonistic activity of delta 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol. , 1987, The Journal of pharmacology and experimental therapeutics.
[404] N. Bowery,et al. GABAA and GABAB receptor site distribution in the rat central nervous system , 1987, Neuroscience.
[405] R. Razdan,et al. Structure-activity relationships of the cannabinoids. , 1986, NIDA research monograph.
[406] R. Mechoulam,et al. Stereochemical requirements for cannabimimetic activity. , 1987, NIDA research monograph.
[407] D. R. Compton,et al. Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids. , 1987, NIDA research monograph.
[408] A. Howlett,et al. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. , 1986, Molecular pharmacology.
[409] J. Penney,et al. Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[410] M. Johnson,et al. A cannabinoid derived prototypical analgesic. , 1984, Journal of medicinal chemistry.
[411] H. Zaugg,et al. New azacannabinoids highly active in the central nervous system. , 1983, Journal of medicinal chemistry.
[412] T. H. Varkony,et al. Stereochemical requirements for cannabinoid activity. , 1980, Journal of medicinal chemistry.
[413] D. McMillan,et al. Discriminative stimulus properties of tetrahydrocannabinols and related drugs in rats and pigeons , 1979, Neuropharmacology.
[414] N. Benowitz,et al. Cardiovascular effects of intravenous delta‐9‐tetrahydrocannabinol: Autonomic nervous mechanisms , 1979, Clinical pharmacology and therapeutics.
[415] J. Howes,et al. Potential therapeutic agents derived from the cannabinoid nucleus. , 1977, Advances in drug research.
[416] L. Harris,et al. Marihuana-like activity of new synthetic tetrahydrocannabinols , 1975, Pharmacology Biochemistry and Behavior.
[417] S. Snyder,et al. Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. , 1975, The Journal of pharmacology and experimental therapeutics.
[418] L. Hollister. Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9-tetrahydrocannabinol. , 1974, Pharmacology.
[419] P. Bender,et al. Cannabinoids. Structure-activity studies related to 1,2-dimethylheptyl derivatives. , 1973, Journal of medicinal chemistry.
[420] D. M. Grilly,et al. Lack of Tolerance to Δ9-Tetrahydrocannabinol in Chimpanzees , 1973, Science.
[421] M. Wall,et al. Intravenous Injection in Man of Δ9-Tetrahydrocannabinol and 11-OH-Δ9-Tetrahydrocannabinol , 1972, Science.
[422] R. Mechoulam,et al. STRUCTURAL REQUIREMENTS FOR CANNABINOID ACTIVITY * , 1971 .
[423] ERNEST L. ABEL,et al. Retrieval of Information after Use of Marihuana , 1971, Nature.
[424] Tadashi. Sasaki,et al. Stereochemistry of the π-route to 2,4-disubstituted adamantanes , 1971 .
[425] F. Korte,et al. Effects of (–) ▵9-trans-Tetrahydrocannabinol and a Synthetic Derivative on Maze Performance of Rats , 1970 .
[426] R. Mechoulam,et al. The absolute configuration of δ1-tetrahydrocannabinol, the major active constituent of hashish. , 1967 .
[427] R. Mechoulam,et al. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .
[428] R. Walton,et al. THE RELATIVE ACTIVITY OF VARIOUS PURIFIED PRODUCTS OBTAINED FROM AMERICAN GROWN HASHISH , 1938 .